Insulin users get a price break under new settlement
Mainers who rely on insulin will now be eligible to purchase monthly supplies of Sanofi insulin products through 2029 for $35 cash, under a new settlement announced by Attorney General Aaron Frey.
The products covered include Admelog, Lantus, Toujeo, Apidra and any biosimilar of those products that Sanofi markets in the U.S., and the new pricing will be available to all consumers, whether or not they have health insurance.
Frey announced the agreement with Sanofi-Aventis U.S. LLC after scrutiny over the company’s pricing of insulin products.
“Insulin is life-sustaining medication and far too many Mainers struggle to afford it,” said Frey. “My office will continue to closely monitor drug pricing and take action to protect consumers to ensure access to these essential medications.”
In addition to the $35 monthly prescription rate, Sanofi will implement an enrollment message program which will alert pharmacists about the patient’s eligibility for this reduced-cost medication when patients are filling their prescriptions.
Mainebiz web partners
Most Recent
Most Recent
0 Comments